WallStSmart

Werewolf Therapeutics Inc (HOWL)vsRevolution Medicines Inc (RVMD)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Werewolf Therapeutics Inc generates 2730% more annual revenue ($21.00M vs $742,000). RVMD leads profitability with a 0.0% profit margin vs -164.8%. HOWL earns a higher WallStSmart Score of 32/100 (F).

HOWL

Avoid

32

out of 100

Grade: F

Growth: 3.7Profit: 4.0Value: 6.7Quality: 4.3
Piotroski: 1/9Altman Z: -11.51

RVMD

Avoid

24

out of 100

Grade: F

Growth: 3.7Profit: 3.0Value: 5.0Quality: 6.0
Piotroski: 1/9Altman Z: -0.99
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

HOWLUndervalued (+86.3%)

Margin of Safety

+86.3%

Fair Value

$4.88

Current Price

$0.96

$3.92 discount

UndervaluedFair: $4.88Overvalued

Intrinsic value data unavailable for RVMD.

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

HOWL2 strengths · Avg: 9.0/10
Operating MarginProfitability
40.6%10/10

Strong operational efficiency at 40.6%

Price/BookValuation
2.8x8/10

Reasonable price relative to book value

RVMD1 strengths · Avg: 9.0/10
Debt/EquityHealth
0.259/10

Conservative balance sheet, low leverage

Areas to Watch

HOWL4 concerns · Avg: 3.0/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$48.04M3/10

Smaller company, higher risk/reward

Piotroski F-ScoreQuality
1/93/10

Weak financial health signals

Return on EquityProfitability
-461.1%2/10

ROE of -461.1% — below average capital efficiency

RVMD4 concerns · Avg: 3.5/10
Price/BookValuation
16.2x4/10

Trading at 16.2x book value

EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Profit MarginProfitability
0.0%3/10

0.0% margin — thin

Operating MarginProfitability
0.0%3/10

Operating margin of 0.0%

Comparative Analysis Report

WallStSmart Research

Bull Case : HOWL

The strongest argument for HOWL centers on Operating Margin, Price/Book.

Bull Case : RVMD

The strongest argument for RVMD centers on Debt/Equity.

Bear Case : HOWL

The primary concerns for HOWL are EPS Growth, Market Cap, Piotroski F-Score.

Bear Case : RVMD

The primary concerns for RVMD are Price/Book, EPS Growth, Profit Margin.

Key Dynamics to Monitor

HOWL profiles as a turnaround stock while RVMD is a value play — different risk/reward profiles.

RVMD carries more volatility with a beta of 1.41 — expect wider price swings.

RVMD is growing revenue faster at -95.2% — sustainability is the question.

HOWL generates stronger free cash flow (7M), providing more financial flexibility.

Bottom Line

HOWL scores higher overall (32/100 vs 24/100). Both earn "Avoid" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Werewolf Therapeutics Inc

HEALTHCARE · BIOTECHNOLOGY · USA

Werewolf Therapeutics, Inc., a biopharmaceutical company, develops therapies designed to boost the body's immune system for the treatment of cancer. The company is headquartered in Cambridge, Massachusetts.

Revolution Medicines Inc

HEALTHCARE · BIOTECHNOLOGY · USA

Revolution Medicines, Inc., a precision clinical-stage oncology company, is focused on developing therapies to inhibit borderline targets in RAS-addicted cancers. The company is headquartered in Redwood City, California.

Want to dig deeper into these stocks?